Biotech News

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Pliant Therapeutics (PLRX)Pliant TherapeuticsEarnings

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief

Related news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

Stock data

Close
0.62 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States